Colorectal cancer (metastatic) - aflibercept [ID514]

Aflibercept for the treatment of metastatic colorectal cancer which has progressed following prior oxaliplatin-based chemotherapy

Status: History
Expected date of issue: TBC
Referral date: February 2012
Process: STA
Notes:

Scoped as part of Batch 21
Topic area:
  • Cancer
  • Digestive system
 

NICE project team

Executive Lead: Carole Longson
Technical Lead: Kumar Perampaladas
Communications manager: Alice Law
Project manager:

Jeremy Powell
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 14 February 2013
1st appraisal committee meeting: 22 May 2013
2nd appraisal committee meeting 23 July 2013
Top


 

Consultees and commentators

Consultees Commentators (no right to submit or appeal)

Manufacturers/sponsors

  • Sanofi (aflibercept)

Patient/carer groups

  • Beating Bowel Cancer

Professional groups

  • Cancer Research UK
  • Royal College of Nursing
  • Royal College of Physicians

Others

  • Department of Health
  • Welsh Government

General

  • Commissioning Support Appraisals Service
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • Healthcare Improvement Scotland
  • Medicines and Healthcare products Regulatory Agency

Possible comparator manufacturer(s)

  • Actavis UK (irinotecan) (not participating)
  • Hospira UK (calcium folinate, irinotecan, fluorouracil) (not participating)
  • Medac UK (irinotecan, fluorouracil) (not participating)
  • Mylan (calcium folinate, irinotecan) (not participating)
  • Pfizer (irinotecan, calcium folinate, calcium levofolinate)
  • Roche (capecitabine)
  • Sandoz (irinotecan, calcium folinate, fluorouracil) (not participating)
  • Teva UK (irinotecan, calcium folinate) (not participating)
  • Wockhardt UK (calcium folinate, fluorouracil) (not participating)

Relevant research groups

Evidence Review Group

  • NHS Centre for Reviews and Dissemination, University of York
  • National Institute for Health Research Health Technology Assessment Programme

Associated guideline groups

  • National Collaborating Centre for Cancer

Associated public health groups

  • tbc

Top


 

Project history

Date Update
22 August 2014 We did not publish the FAD on the website because it contained academic-in-confidence information. This information has now been published. The Final Appraisal Determination and accompanying documents have now been placed on the website to provide all documents related to the guidance development in a transparent way. Therefore, these documents contain information that is highlighted as ‘academic in confidence’ because it was designated as such by the manufacturer at the time when the Final Appraisal Determination was released but has been made publicly available for guidance publication.
25 March 2014 TA307 Colorectal cancer (metastatic) - aflibercept published
24 October 2013 The FAD for the single technology appraisal of aflibercept for treating colorectal cancer [ID514] has been released to consultees and commentators only. It will not be placed on the NICE website at this time. This is because the text of the FAD includes information that is academic in confidence (yet to be published) that was discussed in the public Appraisal Committee meeting and is material to the Appraisal Committee's decision. We are taking this exceptional approach, because we want to proceed with this appraisal so that consultees and commentators are able to consider their response. The next steps of the process remain the same.
Top


 

Key documents

This page was last updated: 26 September 2014